21.06.2016 • NewsElaine BurridgeMaire TecnimontEurochem

Tecnimont Signs for Russian Projects

kodda/Getty Images
kodda/Getty Images

Italian engineering group Maire Tecnimont has signed several agreements for projects in Russia. The first, with Eurochem and Russian construction company Velesstroy, relates to building an ammonia plant in Kingisepp in Leningrad. Tecnimont is currently the engineering, procurement and construction (EPC) contractor on the project and the construction subcontracts are worth around $228 million.

Tecnimont also has signed a Memorandum of Understanding (MoU) with Azot, one of Russia’s largest chemical companies, and construction company Codest, to be EPC contractor for a fertilizer complex Azot is building in Kemerovo in southwestern Siberia. This project comprises plants producing 660,000 t/y ammonia, 396,000 t/y nitric acid, 330,000 t/y porous ammonium nitrate and 412,500 t/y ammonium nitrate solution.

An additional MoU relates to funding a large-scale gas project in Garadagh, near Baku in Azerbaijan for the State Oil Company of Azerbaijan Republic, or Socar. Tecnimont, which has promoted the initiative, said it was best positioned for the project’s EPC phase. As well as a natural gas processing plant, the complex will include a 570,000 t/y PE plant and a 120,000 t/y propylene unit.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read